In conversation with... Kanwal Raghav

from Listen to The Lancet Oncology · host The Lancet

Dr Kanwal Raghav (Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA) discusses his Article entitled, ‘Trastuzumab deruxtecan in HER2-positive advanced colorectal cancer (DESTINY-CRC02): primary results from a randomised, multicentre, phase 2 trial’.

Episode metadata supplied by the publisher feed · Published Aug 28, 2024

Embed this episode

Attribution link and audio player

NOW PLAYING

In conversation with... Kanwal Raghav

0:00 13:22

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of Listen to The Lancet Oncology?

This episode is 13 minutes long.

When was this Listen to The Lancet Oncology episode published?

This episode was published on August 28, 2024.

Can I download this Listen to The Lancet Oncology episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!